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surveillance data collection. Such are defined as an aircraft without a human pilot 
on board, operated either autonomously by computer or under remote control by 
a human pilot. Methods: We performed a targeted literature search for medi-
cal applications of UAS and rank-ordered strengths and weaknesses according to 
emerging applications and corresponding difficulty, feasibility and cost. Results: 
Based on secondary sources, we report conceptual factors that can contribute to the 
practicality and efficiency of UAS in emergency medical situations. These were 1) 
frequency of occurrence, 2) time-sensitivity of occurrence, 3) rurality and complex 
terrain, 4) financial impact and 5) cultural acceptance. The results of our matrix 
point to a gradation of accepted uses for UAS with the variance in geographical 
location and urgency directly relating to an increase in operation costs. It is well 
known that natural disasters are increasing in frequency and intensity. Salient 
platforms for using UAS in medical delivery would be in the areas of natural and 
combative disaster relief. During these occurrences the use of UAS to aid in the 
medical relief could be a great asset. ConClusion: Our model illustrates how Big 
Data can be leveraged to improve ongoing quality and efficiency of UAS-delivered 
medical supplies, reduce time for delivery of supplies during times of natural dis-
asters, and thus eschew our reliance on manned aircraft to assist in critical and 
non-critical medical operations.
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Publication Manual of budget iMPact analysis (bia) by the 
dePaRtMent of science and technology of the MinistRy of health 
(decit)
Koury C.D.N.1, Elias F.T.S.2
1FIPE -Fundação de Ensino e Pesquisas Econômicas, Brasilia, Brazil, 2Ministry of Health of Brazil, 
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The epidemiological and economic methods applied to health technologies evalu-
ations had a significant development in the last two decades. The need to balance 
the incorporation of new technologies in health care and limited financial resources 
promoted the construction and application of instruments supporting the decision 
making of health technology. The requirement Budget Impact Analysis formally 
stated in Law 12.401/2011 establishing the incorporation process technologies in 
SUS. In this context, in 2010/2011, the National Agency of Sanitary Surveillance 
(ANVISA) and DECIT, in partnership Institute for Health Technology Assessment 
(IATS) for drawing up of this guideline. In the first stage of development were 
used international recommendations of Canada, Australia, the UK and Poland, 
the recommendations of the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and the methods used in studies of budgetary impact 
that had already been published. Afterwards, drafted a preliminary version of the 
Guideline and a standard tool - Excel worksheets - to estimate the uptake of mon-
etary resources required for adoption of new technologies. Revisions were carried 
out by technicians DECIT and health agencies, and the proposal was submitted to 
the Working Group on Development of Methodology REBRATS, composed of experts 
and academic researchers from several Brazilian states. Were also carried out work-
shops for the application of spreadsheets. In 2012, the first edition of the Guidelines 
was published two thousand copies in Portuguese in order to provide best practice 
recommendations for studies of budget impact.
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Mixed methods are fast becoming the go-to methodology for the development and 
validation of clinical outcome assessments (COAs). Although mixed methods have 
become popularized for COA development, most of this attention has focussed on 
Rasch measurement theory (RMT). However, the potential utility of mixed methods 
in COA development goes beyond RMT. There is a well-established literature base 
exploring the use of mixed data collection and crossover analyses in social research 
and many of these approaches can be readily applied to COA development. Thus a 
toolkit of methods is proposed which can be pragmatically selected to support the 
development of interpretable and purposeful COAs. Further integration of qualita-
tive and quantitative data throughout the COA development process can serve to 
continually test the evolving hypothesis of the measurement construct and aid 
in evidence triangulation. Data can be transformed to create new data through 
‘quantitizing’ qualitative data and ‘qualitizing’ quantitative data. Qualitative data 
collected during concept elicitation can be converted into binary code allowing 
development of inter- and intra-respondent matrices to explore the frequency 
and intensity of concepts. These data can be subjected to factor, correlational and 
regression analyses to explore the hierarchical structure and inter-relationships of 
qualitatively-derived themes and variables. Concept mapping techniques also allow 
the translation of qualitative data into pictorial form to show “clusters” of, or inter-
relationships between, concepts. This collaborative approach involves stakeholders 
as partners in the research to generate, sort and rate items into conceptual models 
using statistical analyses. There are exciting opportunities to build upon existing 
practice and advance mixed research approaches in the field of COA development. 
Integrating mixed data collection and crossover analyses can enhance the interpret-
ability and purposefulness of COAs ensuring they are developed with an evolving 
hypothesis and fit for purpose. The application of such methods for regulatory COA 
development requires further exploration.
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guidelines used in clinical research: The Cochrane Reviewer’s Handbook and a guide-
line prepared by the The Australian National Health and Medical Research Council. 
The aim of the guideline was to introduce the main concepts through a language 
that is more simple and accessible to health care professionals, familiar or not with 
the methodology of systematic reviews and meta-analyses. This guideline covers 
the three phases of a SR: planning, production and reporting of the SR. It does not 
take into account the impact of the type of question in the review process and does 
not exhaust all the mechanisms necessary in order to understand and perform a 
meta-analysis. It also presents the detailing of some fundamental concepts needed 
to conduct the systematic review in the form of appendices. In 2011, it was given the 
first version of the guideline. DECIT was responsible for the review and publishing 
of the final document. In 2012, the first issue of the guideline was published. The 
importance of the guideline is to orient and standardize the preparation and pro-
duction of a quality SR, mainly due to the gap that exists in the national literature.
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collecting PRos in Patient RegistRies: the need foR and Potential 
iMPact of PRoviding PRo data to the tReating Physician – and when
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The advent of ePROs and direct-to-patient reporting has enabled patients participat-
ing in registries to report their symptom or treatment experiences between physi-
cian visits, with minimal patient burden. These independent reporting approaches 
are often used to support patient retention over long follow-up periods, and/or to 
collect patient-reported data outside of typical physician visit schedules. When a 
patient completes PROs independent of a physician’s presence (i.e., not completed 
at the physician’s office and not entered by the registry site), the treating physician 
may not be aware of the patient’s responses and may need to either proactively 
ask for this information or wait to obtain this information at the end of the study. 
The move toward independent reporting of PRO data introduces several competing 
concerns. First, physician knowledge of the PRO responses could potentially alter 
the naturalistic follow-up in an observational study, if, for example, the physician’s 
knowledge of the PRO response prompts him/her to alter the patient’s treatment. 
As a result, patient reporting independence may be preferred from a research purity 
perspective. However, any PRO response that may be a safety signal would carry 
ethical considerations; in such a case, reporting independence would not be pre-
ferred. If patient care is always paramount to the benefits of research, then it could 
be argued that the optimization of patient care is only possible when the physician 
has all available patient information (e.g., PROs) at his/her disposal, in as close to 
real-time as possible. In addition, some research indicates that patients are more 
likely to complete PROs when their physician is aware of and using the PRO data to 
inform treatment decisions. Further discussion will focus on sponsor and researcher 
responsibilities for funneling observed data on a patient’s experience back to the 
treating physician, drawing on examples from the literature and registry protocols.
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PuRPose: To describe the most effective approaches to achieving a real-world 
study data sample that is representative of the target population. desCRiPtion: 
Considerable attention is paid to the design and analysis of outcomes research 
studies to address internal validity by minimizing bias and confounding. However, 
too often, study sample populations are simply assumed to be representative of 
the study populations from which they are drawn, or are assessed for their repre-
sentativeness only after the study has been conducted. Ideally, sample estimates 
should be as close as possible to their population value in order to make inferences 
about that study population. Practical implementation of measures to avoid selec-
tion bias and ensure a robust sampling procedure can be problematic. Challenges 
include, willingness of sites and patients to participate in research (convenience 
sampling), and management of site and patient drop-out after the study has begun. 
While many database studies and patient registries carry very large sample sizes 
and therefore begin to approximate the target population simply by means of 
sheer size, smaller studies may need to take steps, through stratified sampling 
and enrollment caps, to ensure that the study sample is reflective of the target 
population. These stratification variables may be at the site level (e.g., physician 
specialty, geography), the patient level (age, gender, ethnicity, disease duration) or 
both. Temporal issues may also be problematic where studies performed in the past 
may not reflect rapid changes impacting today’s target population. Following a brief 
overview of the design and analysis considerations, this presentation will focus on 
case examples, drawn from different organizations, of approaches to achieving a 
representative sample, highlighting some of the challenges intrinsic to real-world 
research. Best practice recommendations will be provided to guide researchers on 
the most effective approaches, including the use of reference populations within 
specific countries.
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utilization of unManned aiRcRaft systeMs (uas) foR eMeRgency 
Medical situations in RuRal coMMunities: a vision foR the futuRe
Spitsberg R.1, Jones C.2
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objeCtive: We propose a paradigm and ranking system for potential medical 
applications of unmanned aircraft systems (collectively UAS). Over the past three 
decades, UAS have become a vital component to our armed forces, used notably 
for combat but also commonly used for work in intelligence, reconnaissance and 
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factorial in etiology, there has been a concern about the link between therapy with 
mirtazapine, a heterocyclic antidepressant and the condition. This analysis character-
izes rhabdomyolysis signals for mirtazapine and other antidepressants. Methods: 
Adverse event reports submitted for antidepressants between 1997 and 2012 were 
retrieved from the FDA Adverse Event Reporting System (FAERS). Reporting Odds 
Ratio (ROR) and corresponding 95%CI (ROR05-ROR95) were estimated as a measure of 
disproportional reporting of rhabdomyolysis for individual antidepressants, includ-
ing mirtazapine. The MedDRA preferred term and drug generic names were used for 
event and drug measurement, respectively. Drug-event combinations with ROR05≥ 2.0 
are deemed as signals that warrant further review. Results: There were 1,178 rhab-
domyolysis reports submitted for all antidepressants, 85 reports were for mirtazap-
ine. Signals of rhabdomyolysis (ROR and 95%CI) were detected for mirtazapine (2.62, 
2.2-3.13), clomipramine (2.64, 2.07-3.36), and trimipramine (4.6, 2.64-8.0). There was 
disproportional reporting of rhabdomyolysis for the following agents albeit signal 
threshold was not reached (1< ROR05< 2): amoxapine, maprotiline, amitriptyline, 
rasagiline, citalopram, escitalopram, fluvoxamine, milnacipran, and venlafaxine. As 
a class, antidepressants were not associated with rhabdomyolysis risk (1.28, 0.91-2.02). 
Disproportionality measures were found for heterocyclics (2.10, 1.53-3.0), tricyclics 
(1.52, 1.3-2.34), nonselective monoamino oxidase inhibitors [MAOIs] (0.78, 0.42-1.5), 
selective MAOIs (1.68, 0.9-3.2), selective serotonin reuptake inhibitors [SSRIs] (1.2, 
1.0-1.5), serotonin-norepinephrine reuptake inhibitors [SNRIs] (1.08, 0.82-1.5), and 
other antidepressants (0.62, 0.43-1.1). ConClusions: Rhabdomyolysis is a potential 
risk associated with mirtazapine. In light of inherent limitations of spontaneous 
reporting systems, such as FAERS, signal evaluation activities in real-world data are 
required to further characterize rhabdomyolsysis risk in relation to mirtazapine and 
other antidepressant agents.
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Meta-analysis of dRiveRs of cost-effectiveness fRoM shoRt-teRM 
luRasidone clinical tRials: effect of changing daily dose on Panss 
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objeCtives: Estimates of efficacy and safety are required for economic models 
developed for health technology assessments and provide guidance to decision-
makers regarding the benefit/risk profile of a drug. Studies synthesising clinical trial 
outcomes of atypical antipsychotics in schizophrenia often assume no dose-related 
heterogeneity. The objective of this analysis was to assess dose-related efficacy and 
weight changes after 6 weeks of treatment with lurasidone, an atypical antipsy-
chotic indicated for treatment of schizophrenia at an effective dose range of 20 mg 
to 160 mg/day. Methods: Random-effects meta-analysis was used to synthesize 
evidence from five, 6-week, randomized, double-blind, placebo-controlled studies 
of lurasidone in patients with acute schizophrenia. Outcome measures included 
6-week changes in Positive And Negative Syndrome Scale (PANSS) total score and 
weight (in kg). Results were pooled within and across the daily dose range (40-160 
mg/day) studied in these trials. Results: Pooled mean difference in PANSS total 
score was -8.38 (95% CI: -11.19, -5.56); and in weight was 0.51 kg (95% CI: 0.28, 0.75). 
Between-dose heterogeneity (I-squared= 61.2%, p= 0.006) was introduced by the 160 
mg dose, which was associated with greater treatment effect (mean difference 
-16.20; 95% CI: -21.10, -13.30). Moderate between-study heterogeneity was observed 
in the 40 mg and 120 mg doses (I-squared values were 52.8% and 33.2%, respectively). 
There was no evidence of between-dose or between-study heterogeneity in weight 
gain. ConClusions: Changes in PANSS total score from this meta-analysis sug-
gest that lurasidone in the daily dose range of 40-120 mg had similar efficacy versus 
placebo. The 160 mg daily dose was associated with greater reduction in PANSS total 
score versus placebo; however, this finding was based on evidence from a single 
study. This analysis found no evidence of a dose-related weight gain.
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anticholineRgic Medication use and Risk of deMentia aMong 
eldeRly nuRsing hoMe Residents with dePRession
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1University of Houston, Houston, TX, USA, 2University of Iowa, Iowa City, IA, USA
objeCtives: Use of anticholinergic medications in the elderly can lead to adverse 
cognitive outcomes. This study examined the risk of dementia among elderly nurs-
ing home residents with depression using anticholinergic medications. Methods: 
A nested case-control study was conducted using 2007-2010 Medicare data from all 
states. Patients who had continuous coverage for Medicare Parts A, B and D and no 
HMO coverage during the study period or until death were included. The base cohort 
consisted of residents aged > 65 years, diagnosed with depression, and who did not 
have dementia in 2007 (Baseline Period). Cases were identified as patients who devel-
oped dementia following the baseline period. For each case, 4 age and sex-matched 
controls were selected using incidence density sampling. The primary outcome was 
diagnosis of dementia, between January 1, 2008 and December 31, 2010. Anticholinergic 
exposure was defined using the Anticholinergic Drug Scale (ADS). Prescription of level 
2/3 anticholinergic medications 30 days preceding the event date formed the primary 
exposure. Conditional logistic regression model stratified on matched case-control sets 
was performed to assess the dementia risk, after controlling for baseline sociodemo-
graphic variables and dementia risk factors. Results: The base cohort consisted of 
291,504 elderly residents with depression and without dementia diagnosis. The study 
sample included 49,966 cases diagnosed with dementia and 199,864 matched-controls. 
After adjusting for other covariates, high-level anticholinergic use was associated with 
significant risk of dementia (Relative Risk, RR 1.21; 95% CI, 1.18-1.23) compared to non-
use. The findings remained consistent across levels of anticholinergic potency (Level 
2, RR 1.42, 1.37-147; Level 3, RR 1.07, 1.09-1.15). ConClusions: Use of anticholinergic 
medications was associated with a higher risk of dementia compared to no use among 
elderly residents with depression. With increasing evidence regarding cognitive effects 
of anticholinergics, there is a significant need to optimize anticholinergic use, espe-
cially for those who are at-risk for dementia.
Methods for developing new Clinical Outcome Assessments (COAs) are well-estab-
lished and documented. While the COA development literature emphasizes the 
importance of linguistic and cultural equivalence, exact methods to achieve this are 
often not clearly presented. For multinational or multicultural studies, Simultaneous 
Item Development (SID) of a COA in all languages and cultural groups required for 
the research program is the most efficient approach to ensure valid COA data and 
interpretable results. This is because SID increases the likelihood the COA data col-
lected in multiple languages or cultures will be conceptually equivalent and culturally 
relevant.As published information explaining how to implement SID is limited, this 
presentation provides an overview of a purposeful and pragmatic (recognising the 
practical challenges associated with COA development) SID approach that incor-
porates both qualitative and quantitative methodologies.In our experience, SID is 
valuable at four stages of COA development: concept elicitation, item generation, 
cognitive testing, and content harmonization. Generally, SID is most efficient when 
a single reference or ‘core’ version is used throughout the four stages (typically the 
English language version for the UK or United States). Activities at each stage are 
managed by researchers fluent in the language for the core version. Their primary 
objective is to ensure that the core COA version has a clear conceptual framework 
that evolves in a consistent manner across language/culture versions at each stage 
so that measured concepts are equivalent in the different language versions.We will 
discuss how use of SID at each stage can aid researchers in developing COAs that are 
patient-centred, understandable, and content relevant across languages and cultures. 
Challenges commonly faced in SID of COA will be discussed as will practical solutions 
to these challenges.
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objeCtives: Determine growth and focal points for the development of health 
economics in Latin America, through the classification methodology proposed by 
Wagstaff and Culyer. Methods: From the results of the development of a literature 
review of health economics for Latin America in Scopus Database were classified 
the articles found in twelve groups of different general items, which were proposed 
by Wagstaff and Culyer in 2012, based on the Williams defining nodes 1989. It was 
analyzed the changes of production trends, as well as countries and institutions 
which developed the matter. Results: Production trend changes were found from 
1997, where an annual growth of over 50% of production for each year is evident, 
until 2003. With regard to issues of production about 52% focus on public health, as 
an item of the twelve general items, followed by the production of 20% in economic 
evaluation. Universities and institutions are presented with further development of 
the field, under the creation of courses, masters and specialization, and the creation 
of research groups. ConClusions: Taking as a reference these studies it is possible 
to find those areas that can be generated processes use and development of an entire 
scientific field, such as health economics, and not exhaust the use of a few tools on 
whims or vices of health systems.
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objeCtives: Resource modelling has been largely ignored in health technology 
assessment (HTA) and this paper argues the need for it to be considered as a separate 
set of analyses to deal with the issue of implementation and feasibility. Methods: 
Economic evaluation and budget impact models, which are the two economic analy-
ses that currently feed into HTA, are briefly described before highlighting their limita-
tions in informing issues of feasibility and implementation. Resource modelling is 
defined as the quantitative assessment of technology diffusion curves, their related resource 
requirements and their capacity constraints. The resource modelling examples from the 
literature include studies performed alongside traditional economic evaluation meth-
ods such as CEA or BIA and studies that were performed in the field of health care 
operational research. Results: Resource modelling can be performed using a num-
ber of different approaches. However, there are a number of general issues that need 
to be considered when choosing the appropriate resource modelling methodology 
and these include a) understand the different types of resources, b) the characteristics 
of different resource modelling techniques and, c) challenges for the generalising the 
estimation and validity of resource modelling results. ConClusions: Guidelines are 
provided as to when resource modelling is necessary i.e. when it should be used. The 
next issue is about the choice of methodology and this relates the level of resource 
use detail required. A related question is whether a standard exercise is enough for 
the whole jurisdiction or whether bespoke evaluations need to be performed for dif-
ferent local settings in the jurisdiction. Finally, the choice of data is also linked to the 
type of methodology chosen for resource modelling.
disease-sPecific studies
Mental health – clinical outcomes studies
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RhabdoMyolysis Risk
Ali A.K.
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objeCtives: Among other factors, the breakdown of skeletal muscle fibers (rhabdo-
myolysis) is a leading cause of acute kidney failure. While rhabdomyolysis is multi-
